a third. The large number of stillbirths due to malaria, even when treated, are indicative of the failure of health strategies available for women only when they are pregnant. These include bednet distribution and intermittent preventive treatment of malaria (which is further compounded by increasing resistance to sulfadoxine pyrimethamine) delivered at antenatal care in Africa. 4 Reducing malaria in the general population will reduce malaria deaths, including stillbirths. However, policy makers and funding agents cannot overlook the need to identify preventive interventions that are costeffective and efficacious and diagnostic tools targeted for malaria in pregnancy to achieve WHO and UNICEF's Every Newborn Action Plan to end preventable stillbirths by 2035. 5 We declare no competing interests. 
The invisible burden of malaria-attributable stillbirths
The highly anticipated publication of the updated malaria maps in The Lancet 1 shows that despite the substantial progress made since 2000, mortality gains have stalled and there were 618 700 (95% CI 368 600-952 200) deaths due to malaria globally in 2017, most of which occurred in subSaharan Africa (545 200 [88%]). However, mortality calculations ignore malariaattributable stillbirths because data on fetal death are not captured in standard estimates of infant and under5 mortality.
Using global estimates of malaria, stillbirth, and estimated relative increase in risk of stillbirth associated with malaria exposure, we estimate that across all WHO regions in 2015, between 126 109 (95% CI 51 632-218 474) and 207 971 (125 723-303 396) stillbirths were attributable to malaria, depending on the treatment coverage of malaria in pregnancy (appendix). [1] [2] [3] Ignoring stillbirths can significantly underestimate the true burden of malariaattributable mortality by up to See Online for appendix
Authors' reply
We thank Freya J I Fowkes and colleagues for their comments on our study. 1 We wholeheartedly agree that malaria, and in particular Plasmodium falciparum in subSaharan Africa, imposes a large and entirely unacceptable toll in stillbirths alongside the more evident burden of morbidity and mortality.
We also agree that this burden is inadequately understood and that greater attention is required if global targets for reducing preventable stillbirth are to be met.
In keeping with the causespecific components of the Global Burden of Disease Study 2017, 2 the focus of our study was on the estimation of fatal and nonfatal outcomes of malaria, with the denominator population limited to livebirths.
We commend the authors for their integration of these new results with current evidence on the elevated risk of stillbirth imposed by P falciparum infection to yield updated estimates of malaria's contribution to global stillbirths. The numbers underscore the magnitude of the problem and provide a powerful advocacy message.
The necessarily simple calculations presented serve to highlight the current paucity of data and approaches that could yield estimates with greater geographical and temporal richness. Such granular information is potentially vital if progress in preventing malaria attributable stillbirth is to be accelerated. Improving case management rates for pregnant women infected with malaria will be assisted by pinpointingat both national and subnational scales-where the largest shortfalls in treatment exist. Effective targeting of current preventive strategies, in particu lar intermittent preventive treatment in pregnancy, can be enhanced with detailed information on the respective geographical distributions of pregnant women and transmission risk, as well as ongoing monitoring of sulfadoxine pyrimethamine efficacy.
However, Fowkes and colleagues also show how the optimisation of prematurely because of an excess of heart failure incidence.
Because all available endothelin A receptor antagonists attenuate the vasoconstriction of efferent arteriole and reduce hyperfiltration, 3 it seems inevitable that endothelin A receptor antagonists would induce fluid reten tion and thereby have a risk of heart failure. Thus, it was crucial for these patients to choose optimal diuretic strategy to prevent heart failure.
Although more than 85% of indi viduals took conventional diuretics, including loops and thiazides (1131 [85%] of 1325 in the atrasentan group vs 1158 [88%] of 1323 in the placebo group), heart failure attributed to atrasentan was not well controlled (6% in the atrasentan group vs 4% in the placebo group [p=0·064]). By contrast, the selective vasopressin V2receptor antagonist tolvaptan, in addition to standard therapy (eg, diuretics), has been shown to promote excretion of electrolytefree water and improve signs and symptoms of heart failure in patients with and without diabetes. 4 Moreover, tolvaptan could reduce albuminuria when compared with placebo. 5 In view of these facts, the V2receptor antagonists should be added to conventional diuretics in the trial of atrasentan.
We declare no competing interests. calculated as 2·2 years, figure 3 in the Article 1 shows that after 42 weeks of followup, doubling of creatinine and endstage renal disease were analysed in 103 patients in the placebo group and 108 in the atrasentan group. This could significantly reduce the clinical value of the atrasentan in clinical practice. Furthermore, could the authors explain why the doubling of serum creatinine has been identified as part of the composite primary endpoint? Because of the wide patient age range (ages 18−85 years) and the ethical diversity, the authors should calculate and ana lyse the estimated glomerular filtra tion rate to provide a more accurate predictive value of renal function.
Heerspink and colleagues included patients that were likely to exhibit a renal benefit by using atrasentan into the study population. We find that the definition applied to select patients with potential renal benefit should be disclosed because a kidney biopsy was not included in the study.
We declare no competing interests. existing strategies alone might not be sufficient to alleviate malaria related stillbirth. The introduction of additional intervention approachesperhaps aimed at reducing infection earlier during pregnancy or even before conception-will again probably benefit from spatial intelligence identifying target populations relative to risk.
In summary, we concur with the authors on the important and ongoing contribution of malaria to the burden of stillbirths, and advocate for frameworks to be developed that can better characterise this burden to provide operational information to accelerate its decline.
